Literature DB >> 21972209

Epigenetics and mutations in chronic myeloproliferative neoplasms.

Alessandro M Vannucchi, Flavia Biamonte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21972209      PMCID： PMC3186298          DOI： 10.3324/haematol.2011.052068

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

Review 1.  Advances in understanding and management of myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Ayalew Tefferi
Journal:  CA Cancer J Clin       Date:  2009-04-15       Impact factor: 508.702

2.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

3.  Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor.

Authors:  Yang-Sook Cho; Eun-Joo Kim; Ui-Hyun Park; Hong-Sig Sin; Soo-Jong Um
Journal:  J Biol Chem       Date:  2006-04-10       Impact factor: 5.157

4.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.

Authors:  Cynthia L Fisher; Nicolas Pineault; Christy Brookes; Cheryl D Helgason; Hideaki Ohta; Caroline Bodner; Jay L Hess; R Keith Humphries; Hugh W Brock
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

5.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

6.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

7.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Authors:  Omar Abdel-Wahab; Taghi Manshouri; Jay Patel; Kelly Harris; Jinjuan Yao; Cyrus Hedvat; Adriana Heguy; Carlos Bueso-Ramos; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

8.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Authors:  Franz X Schaub; Renate Looser; Sai Li; Hui Hao-Shen; Thomas Lehmann; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

9.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

10.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962
View more
  8 in total

Review 1.  Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Authors:  B L Stein; R Swords; A Hochhaus; F Giles
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

2.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

3.  Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.

Authors:  Paola Guglielmelli; Andrea Bisognin; Claudia Saccoman; Carmela Mannarelli; Alessandro Coppe; Alessandro M Vannucchi; Stefania Bortoluzzi
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

4.  ASXL1 plays an important role in erythropoiesis.

Authors:  Hui Shi; Shohei Yamamoto; Mengyao Sheng; Jie Bai; Peng Zhang; Runze Chen; Shi Chen; Lihong Shi; Omar Abdel-Wahab; Mingjiang Xu; Yuan Zhou; Feng-Chun Yang
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

5.  RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.

Authors:  Rabindranath Bera; Ming-Chun Chiu; Ying-Jung Huang; Tung-Huei Lin; Ming-Chung Kuo; Lee-Yung Shih
Journal:  J Hematol Oncol       Date:  2019-10-22       Impact factor: 17.388

6.  JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.

Authors:  Alexandra Wolf; René Eulenfeld; Karoline Gäbler; Catherine Rolvering; Serge Haan; Iris Behrmann; Bernd Denecke; Claude Haan; Fred Schaper
Journal:  JAKSTAT       Date:  2013-04-08

7.  A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.

Authors:  E Calura; S Pizzini; A Bisognin; A Coppe; G Sales; E Gaffo; T Fanelli; C Mannarelli; R Zini; R Norfo; V Pennucci; R Manfredini; C Romualdi; P Guglielmelli; A M Vannucchi; S Bortoluzzi
Journal:  Blood Cancer J       Date:  2016-06-24       Impact factor: 11.037

Review 8.  Epigenetics in Myeloproliferative Neoplasms.

Authors:  Suzanne McPherson; Mary Frances McMullin; Ken Mills
Journal:  J Cell Mol Med       Date:  2017-07-04       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.